The comparative one-year performance of anti–tumor necrosis factor α drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: Results from a longitudinal, observational, multicenter study-Reference-Cited by-同舟云学术

The comparative one-year performance of anti–tumor necrosis factor α drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: Results from a longitudinal, observational, multicenter study

Published:2008 Issue:2 Volume:59 Page:234-240
ISSN:0004-3591
Container-title:Arthritis & Rheumatism
language:en
Short-container-title:Arthritis Rheum

Author:

Heiberg Marte Schrumpf,Koldingsnes Wenche,Mikkelsen Knut,Rødevand Erik,Kaufmann Cecilie,Mowinckel Petter,Kvien Tore K.

Publisher

Wiley

Subject

Pharmacology (medical),Immunology,Rheumatology,Immunology and Allergy

Reference28 articles.

1. ASAS/EULAR recommendations for the management of ankylosing spondylitis

2. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial

3. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: An open, observational, extension study of a three-month, randomized, placebo-controlled trial

4. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial

Cited by 220 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment with Targeted Therapy in Patients with Psoriatic Arthritis and Inadequate Response to Methotrexate: Proposal for a Rational Strategy;Rheumatology and Therapy;2024-08-12

2. A systematic review of sex and gender differences in treatment outcome of inflammatory skin diseases: Is it time for new guidelines?;Journal of the European Academy of Dermatology and Venereology;2024-07-30

3. No difference in clinical parameters and drug retention in PsA patients receiving b/tsDMARD monotherapy versus combination with methotrexate: data from the RABBIT-SpA registry;RMD Open;2024-07

4. Retention rate of subcutaneous TNF inhibitors in axial spondyloarthritis in a multicentre study from the RIC-FRANCE network;Scientific Reports;2024-01-16

5. Correction: Influence of sex on the persistence of different classes of targeted therapies for psoriatic arthritis: a cohort study of 14 778 patients from the French health insurance database (SNDS);RMD Open;2024-01